|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 胆固醇酯转移蛋白基因的蛋白质截断型变异体与冠状动脉性心脏病风险的关系显示文摘随机对照试验结果表明,抑制胆固醇酯转运蛋白(cholesteryl ester transfer protein,CETP)的疗法并不能降低冠状动脉性心脏病(coronary heart disease,CHD)的发生风险。研究失败的可能原因包括靶目标无效、靶目标外小分子的不良反应和随机对照设计因素影响等。在编码药物靶点的基因中具有天然存在的遗传变异,以此为基础,人类研究可以深入了解针对基因产物的治疗的潜在功效和安全性。 | Nomura A Won HH Khera AV Takeuchi F Ito K McCarthy S Emdin CA Klarin D Natarajan P Zekavat SM Gupta N Peloso GM Borecki IB Teslovich TM Asselta R Duga S Merlini PA Correa A Kessler T Wilson JG Bown MJ Hall AS Braund PS Carey DJ Murray MF Kirchner HL Leader JB Lavage DR Manus JN Hartze DN Samani NJ Schunkert H Marrugat J Elosua R McPherson R Farrall M Watkins H Juang JJ Hsiung CA Lin SY Wang JS Tada H Kawashiri MA Inazu A Yamagishi M Katsuya T Nakashima E Nakatochi M Yamamoto K Yokota M Momozawa Y Rotter JI Lander ES Rader DJ Danesh J Ardissino D Gabriel S Willer CJ Abecasis GR Saleheen D Kubo M Kato N Ida Chen YD Dewey FE Kathiresan S 刘莉 叶鹏 | 2017 | 中华高血压杂志2017，25，9： | 2 |
| 2 | Cholesterol efl'lox capacity, high-density lipoprotein function, and atheroscle- rosis显示文摘 | Khera AV Cuehel M de la Llera-Moya LM | 2011 | N Engl J Med2011，364，2： | 1 |
| 3 | On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy thrombolysis in myocardial infarction 22 study)显示文摘 | Khera AV Wolfe ML Cannon CP | 2010 | Am J Cardiol2010，106，4： | 1 |
| 4 | Cholesterol efflux ca- pacity, high-density lipoprotein function, and atherosclerosis显示文摘 | Khera AV Cuchel M de la Llera-Moya M | 2011 | N Engl J Med2011，364，2： | 1 |
| 5 | The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary synrome but not in stable coronary artery disease显示文摘 | Patel PJ Khera AV Jafri K | 2011 | JACC2011，58，20： | 1 |
| 6 | Future therapeutic directions in reversecholesterol transport显示文摘 | Khera AV Rader DJ | 2010 | Curr Atheroscler Rep2010，12，： | 1 |
| 7 | The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease显示文摘 | Patel PJ Khera AV Jafri K | | 0，，20： | 1 |
| 8 | Cholesterol efflux capacity,high-density lipoprotein function,and atherosclerosis显示文摘 | Khera AV Cuchel M de la Llera-Moya M | | 0，，： | 1 |
| 9 | Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis 显示文摘 | Khera AV Cuchel M de la Llera-Moya M | 2011 | N Engl J Med2011，364，2： | 1 |
| 10 | Cholesterol efflux capacity,high-density lipoprotein function,and atherosclerosis显示文摘 | Khera AV Cuchel M de la Llera-Moya M | | 0，，2： | 1 |
| 11 | The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease显示文摘 | Patel PJ Khera AV Jafri K | 2011 | J Am Coll Cardiol2011，58，20： | 1 |
| 12 | Lipoprotein(a)concen- trations,rosuvastatin therapy,and residual vascular risk;An analysis from the JUPITER trial(justification for the use of statins in preven- tion:An intervention trial evaluating rosuvastatin)显示文摘 | Khera AV Everett BM Caulfield MP | 2014 | Circulation: An Official Journal of the American Heart Association2014，129，6： | 1 |
| 13 | On-statin eholesteryl es-tertransfer protein mass and risk of recurrent coronary events( from the pravastatin or atorvastatin evaluation and infection therapy - thrombolysisin myocardial infarction 22 study) 显示文摘 | Khera AV Wolfe ML Cannon CP | 2010 | Am J Chin Med2010，106，4： | 1 |
| 14 | Choles- terol efflux capacity, high-density lipoprotein function, and atherosclerosis显示文摘 | Khera AV Cuchel M de la Llera-Moya M | 2011 | N Engl J Med2011，364，2： | 1 |
| 15 | Cholesterol effluxcapacity, high-density lipoprotein function, and atherosclerosis 显示文摘 | Khera AV Cuchel M de la Llera-Moya M | 2011 | N Engl J Med2011，364，2： | 1 |
| 16 | Selenium supplementa- tion protects trophoblast ceils from mitochondrial oxidative stress显示文摘 | Khera A Vanderlelie JJ Perkins AV | 2013 | Placenta2013，34，： | 1 |
| 17 | Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decomponsated heart failure 显示文摘 | Testani JM Khera AV St John | 2010 | Am J Cardiol2010，105，4： | 1 |
| 18 | On -statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy - thrombolysis in myocardial infarction 22 study) 显示文摘 | Khera AV Wolfe ML Cannon CP | 2010 | Am J Cardiol2010，106，4： | 1 |
| 19 | Cholesterol efflux capaci- ty, high-density lipoprotein function, and atherosclerosis 显示文摘 | Khera AV Cuchel M Llera-Moya M | 2011 | N Engl J Med2011，364，2： | 1 |
| 20 | The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease 显示文摘 | Patel PJ Khera AV Jafri K | 2011 | J Am Coll Cardiol2011，58，20： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员